ASH Letter to FDA re Draft on Collection of Race and Ethnicity Data in Clinical Trials and Studies
Apr 26
2024
American Society of Hematology. (2024).
ASH Letter to FDA re Draft on Collection of Race and Ethnicity Data in Clinical Trials and Studies.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-on-collection-of-race-and-ethnicity-data-in-clinical-trials-and-studies.
American Society of Hematology.
"ASH Letter to FDA re Draft on Collection of Race and Ethnicity Data in Clinical Trials and Studies." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-on-collection-of-race-and-ethnicity-data-in-clinical-trials-and-studies
(label-accessed October 11, 2024).
"American Society of Hematology."
ASH Letter to FDA re Draft on Collection of Race and Ethnicity Data in Clinical Trials and Studies, 11 Oct. 2024 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-on-collection-of-race-and-ethnicity-data-in-clinical-trials-and-studies.
